Boehringer Ingelheim GmbH  Boehringer Ingelheim GmbH

Release Summary

Sub-analyses of RE-DUAL PCI™: reductions in incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy

Boehringer Ingelheim GmbH